We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Cardinal (CAH) Q4 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Cardinal Health (CAH - Free Report) will report quarterly earnings of $2.03 per share in its upcoming release, pointing to a year-over-year increase of 10.3%. It is anticipated that revenues will amount to $60.67 billion, exhibiting an increase of 1.3% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Pharmaceutical and Specialty Solutions' stands at $55.86 billion. The estimate points to a change of +0.5% from the year-ago quarter.
Analysts forecast 'Revenue- Other' to reach $1.57 billion. The estimate points to a change of +33.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Medical Products and Distribution' should arrive at $3.21 billion. The estimate points to a change of +3.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Segment profit- Pharmaceutical and Specialty Solutions' will likely reach $543.86 million. Compared to the present estimate, the company reported $482.00 million in the same quarter last year.
Analysts expect 'Segment profit- Other' to come in at $147.91 million. Compared to the present estimate, the company reported $111.00 million in the same quarter last year.
Cardinal shares have witnessed a change of -4.7% in the past month, in contrast to the Zacks S&P 500 composite's +1.2% move. With a Zacks Rank #2 (Buy), CAH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Cardinal (CAH) Q4 Earnings
Wall Street analysts forecast that Cardinal Health (CAH - Free Report) will report quarterly earnings of $2.03 per share in its upcoming release, pointing to a year-over-year increase of 10.3%. It is anticipated that revenues will amount to $60.67 billion, exhibiting an increase of 1.3% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Pharmaceutical and Specialty Solutions' stands at $55.86 billion. The estimate points to a change of +0.5% from the year-ago quarter.
Analysts forecast 'Revenue- Other' to reach $1.57 billion. The estimate points to a change of +33.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Medical Products and Distribution' should arrive at $3.21 billion. The estimate points to a change of +3.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Segment profit- Pharmaceutical and Specialty Solutions' will likely reach $543.86 million. Compared to the present estimate, the company reported $482.00 million in the same quarter last year.
Analysts expect 'Segment profit- Other' to come in at $147.91 million. Compared to the present estimate, the company reported $111.00 million in the same quarter last year.
View all Key Company Metrics for Cardinal here>>>Cardinal shares have witnessed a change of -4.7% in the past month, in contrast to the Zacks S&P 500 composite's +1.2% move. With a Zacks Rank #2 (Buy), CAH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .